ProteoFormiX

ProteoFormiX is a Belgian biotechnology company specializing in the discovery of disease-associated proteoforms using a proprietary top-down proteomics and mass spectrometry imaging platform. Founded in 2017 as a spin-off from Ghent University, the company focuses on identifying specific protein variants (proteoforms) from biobanked clinical tissues, including formaldehyde-fixed, paraffin-embedded (FFPE) samples. Its technology is applied across multiple therapeutic areas, including neurodegeneration, oncology, and ophthalmology, to develop innovative biomarkers for drug discovery and diagnostics. The company operates as a translational partner for pharmaceutical and clinical researchers, aiming to bridge the gap between proteomic research and clinical application.